The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC).
T. Y. Seiwert
Consultant or Advisory Role - Bristol-Myers Squibb (U)
D. J. Haraf
No relevant relationships to disclose
E. E. Cohen
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
E. A. Blair
No relevant relationships to disclose
K. Stenson
No relevant relationships to disclose
J. K. Salama
No relevant relationships to disclose
M. Kocherginsky
No relevant relationships to disclose
V. M. Villaflor
Stock Ownership - Bristol-Myers Squibb
M. Witt
No relevant relationships to disclose
R. Williams
No relevant relationships to disclose
A. Dekker
No relevant relationships to disclose
E. E. Vokes
Consultant or Advisory Role - Bristol-Myers Squibb; ImClone Systems
Honoraria - Bristol-Myers Squibb; ImClone Systems